Dako, a Danish provider of cancer diagnostics solutions, has received approval from the US Food and Drug Administration to market HercepTest and HER2 FISH pharmDx Kit as companion diagnostics for pertuzumab (Perjeta) - a new Genentech ...
Tags: Dako, cancer diagnostics solutions, HercepTest, HER2 FISH
The US Food and Drug Administration (FDA) has approved Genentech's Perjeta (pertuzumab) for the treatment of HER2-positive metastatic breast cancer (mBC), in combination with Herceptin (trastuzumab) and docetaxel chemotherapy. The ...
Tags: FDA approval, breast cancer, clinical study, pharmaceutical product
Exelixis has completed the submission of new drug application (NDA) for cabozantinib as a treatment for progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC) patients, with the FDA. Cabozantinib is ...
Tags: submission of new drug application, FDA, pharmaceutical product
Sanofi and Regeneron Pharmaceuticals have received FDA priority review for the biologics license application (BLA) of ZALTRAP (aflibercept) as a treatment for metastatic colorectal cancer (mCRC). The filing was based on the Phase III ...
More than 80 percent of people with pancreatic cancer are diagnosed after the cancer has metastasized, and by then the prognosis for long-term survival is dismal. However, surgeons and scientists at the University of California-San Diego ...
Tags: fluorescent light
More than 80 percent of people with pancreatic cancer are diagnosed after the cancer has metastasized, and by then the prognosis for long-term survival is dismal. However, surgeons and scientists at the University of California-San Diego ...
Tags: Market View, fluorescent light